Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Breast Neoplasms 7244Neoplasms 4539Prostatic Neoplasms 3489Colorectal Neoplasms 2940Carcinoma, Non-Small-Cell Lung 2831Lung Neoplasms 2547Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1874Multiple Myeloma 1811Carcinoma, Hepatocellular 1733Neoplasm Metastasis 1585Stomach Neoplasms 1502Lymphoma 1457Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1435Brain Neoplasms 1373Melanoma 1348Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1255Colonic Neoplasms 1204Glioblastoma 1138Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1066Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

ceftolozane, tazobactam drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × Pseudomonas Infections × Clear all
NCT04673175 2026-01-21

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

Weill Medical College of Cornell University

Phase 4 Terminated
17 enrolled 20 charts
Other hematologic neoplasm

Pneumonia, Pseudomonas Infections, Bacteremia, Gram-Negative Bacterial Infections, Hematologic Neoplasms

NCT05975151 2023-09-21

Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Qilu Hospital of Shandong University

Phase 2 Unknown
63 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Pseudomonas Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡